X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ASTRAZENECA PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA ASTRAZENECA PHARMA ABBOTT INDIA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 32.8 93.7 35.1% View Chart
P/BV x 8.2 13.3 61.5% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ABBOTT INDIA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
ASTRAZENECA PHARMA
Mar-14
ABBOTT INDIA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,0151,285 468.1%   
Low Rs3,707634 584.7%   
Sales per share (Unadj.) Rs1,236.9189.6 652.4%  
Earnings per share (Unadj.) Rs122.2-0.2 -60,009.2%  
Cash flow per share (Unadj.) Rs129.03.8 3,354.9%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.268.6 759.4%  
Shares outstanding (eoy) m21.2525.00 85.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.95.1 77.7%   
Avg P/E ratio x39.8-4,712.7 -0.8%  
P/CF ratio (eoy) x37.7249.6 15.1%  
Price / Book Value ratio x9.314.0 66.7%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,29623,988 430.6%   
No. of employees `0003.01.6 189.6%   
Total wages/salary Rs m3,3701,605 210.0%   
Avg. sales/employee Rs Th8,891.83,040.2 292.5%   
Avg. wages/employee Rs Th1,140.01,029.2 110.8%   
Avg. net profit/employee Rs Th878.3-3.3 -26,901.6%   
INCOME DATA
Net Sales Rs m26,2844,740 554.6%  
Other income Rs m50492 547.7%   
Total revenues Rs m26,7894,832 554.4%   
Gross profit Rs m3,665-130 -2,823.9%  
Depreciation Rs m144101 142.7%   
Interest Rs m80-   
Profit before tax Rs m4,017-139 -2,892.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,4215 27,917.5%   
Profit after tax Rs m2,596-5 -51,007.9%  
Gross profit margin %13.9-2.7 -509.2%  
Effective tax rate %35.4-3.7 -965.3%   
Net profit margin %9.9-0.1 -9,198.0%  
BALANCE SHEET DATA
Current assets Rs m14,4462,726 529.9%   
Current liabilities Rs m4,7252,435 194.0%   
Net working cap to sales %37.06.1 601.6%  
Current ratio x3.11.1 273.1%  
Inventory Days Days5174 69.7%  
Debtors Days Days2041 48.0%  
Net fixed assets Rs m1,1131,035 107.5%   
Share capital Rs m21350 425.0%   
"Free" reserves Rs m10,808942 1,146.8%   
Net worth Rs m11,0761,716 645.5%   
Long term debt Rs m00-   
Total assets Rs m16,2414,156 390.8%  
Interest coverage x497.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.61.1 141.9%   
Return on assets %16.0-0.1 -13,093.6%  
Return on equity %23.4-0.3 -7,902.3%  
Return on capital %36.30-  
Exports to sales %0.65.7 10.8%   
Imports to sales %12.66.5 195.6%   
Exports (fob) Rs m162270 59.8%   
Imports (cif) Rs m3,322306 1,084.7%   
Fx inflow Rs m268375 71.5%   
Fx outflow Rs m3,927470 835.4%   
Net fx Rs m-3,659-96 3,829.8%   
CASH FLOW
From Operations Rs m2,514-8 -31,040.7%  
From Investments Rs m-800-146 548.7%  
From Financial Activity Rs m-803862 -93.1%  
Net Cashflow Rs m912709 128.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 7.9 0.3 2,633.3%  
FIIs % 0.1 15.7 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 9.1 187.9%  
Shareholders   18,270 12,856 142.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NOVARTIS  NATCO PHARMA  BIOCON LTD  IPCA LABS  ALKEM LABORATORIES  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS